178 related articles for article (PubMed ID: 34422720)
1. A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells
El-Soussi S; Hanna R; Semaan H; Khater AR; Abdallah J; Abou-Kheir W; Abou-Antoun T
Front Pediatr; 2021; 9():693145. PubMed ID: 34422720
[TBL] [Abstract][Full Text] [Related]
2. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
[TBL] [Abstract][Full Text] [Related]
3. A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90 Inhibition in MYCN-Amplified Neuroblastoma Cells.
Hanna R; Abdallah J; Abou-Antoun T
Front Oncol; 2020; 10():624560. PubMed ID: 33569349
[TBL] [Abstract][Full Text] [Related]
4. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.
Chang WI; Honeyman JN; Zhang J; Lin C; Sharma A; Zhou L; Oliveira J; Tapinos N; Lulla RR; Prabhu VV; El-Deiry WS
Am J Cancer Res; 2023; 13(12):6241-6255. PubMed ID: 38187038
[TBL] [Abstract][Full Text] [Related]
5. ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer.
Tucker K; Yin Y; Staley SA; Zhao Z; Fang Z; Fan Y; Zhang X; Suo H; Sun W; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL
Am J Cancer Res; 2022; 12(2):521-536. PubMed ID: 35261784
[TBL] [Abstract][Full Text] [Related]
6. L1-CAM knock-down radiosensitizes neuroblastoma IMR-32 cells by simultaneously decreasing MycN, but increasing PTEN protein expression.
Rached J; Nasr Z; Abdallah J; Abou-Antoun T
Int J Oncol; 2016 Oct; 49(4):1722-30. PubMed ID: 27432152
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
[TBL] [Abstract][Full Text] [Related]
8. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer.
Staley A; Tucker K; Yin Y; Zhang X; Fan Y; Zhang Y; Fang Z; Sun W; Suo H; Zhao X; Zhao Z; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL
Am J Cancer Res; 2021; 11(11):5374-5387. PubMed ID: 34873466
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
10. ONC201 Suppresses Neuroblastoma Growth by Interrupting Mitochondrial Function and Reactivating Nuclear ATRX Expression While Decreasing MYCN.
Wu JC; Huang CC; Wang PW; Chen TY; Hsu WM; Chuang JH; Chuang HC
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675163
[TBL] [Abstract][Full Text] [Related]
11. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
[TBL] [Abstract][Full Text] [Related]
12. Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis.
Jacobson JC; Qiao J; Clark RA; Chung DH
Discov Oncol; 2022 Oct; 13(1):103. PubMed ID: 36227363
[TBL] [Abstract][Full Text] [Related]
13. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.
Megison ML; Stewart JE; Nabers HC; Gillory LA; Beierle EA
Clin Exp Metastasis; 2013 Jun; 30(5):555-68. PubMed ID: 23208732
[TBL] [Abstract][Full Text] [Related]
14. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
15. High mobility group A1 is a molecular target for MYCN in human neuroblastoma.
Giannini G; Cerignoli F; Mellone M; Massimi I; Ambrosi C; Rinaldi C; Dominici C; Frati L; Screpanti I; Gulino A
Cancer Res; 2005 Sep; 65(18):8308-16. PubMed ID: 16166307
[TBL] [Abstract][Full Text] [Related]
16. ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer
Zhang Y; Huang Y; Yin Y; Fan Y; Sun W; Zhao X; Tucker K; Staley A; Paraghamian S; Hawkins G; Prabhu V; Allen JE; Zhou C; Bae-Jump V
Front Oncol; 2020; 10():577141. PubMed ID: 33194693
[TBL] [Abstract][Full Text] [Related]
17. JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells.
Kuo YT; Liu YL; Adebayo BO; Shih PH; Lee WH; Wang LS; Liao YF; Hsu WM; Yeh CT; Lin CM
PLoS One; 2015; 10(5):e0125343. PubMed ID: 25951238
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
19. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
[TBL] [Abstract][Full Text] [Related]
20. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
Przystal JM; Cianciolo Cosentino C; Yadavilli S; Zhang J; Laternser S; Bonner ER; Prasad R; Dawood AA; Lobeto N; Chin Chong W; Biery MC; Myers C; Olson JM; Panditharatna E; Kritzer B; Mourabit S; Vitanza NA; Filbin MG; de Iuliis GN; Dun MD; Koschmann C; Cain JE; Grotzer MA; Waszak SM; Mueller S; Nazarian J
Neuro Oncol; 2022 Sep; 24(9):1438-1451. PubMed ID: 35157764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
